Investor Conference Attendance
TheraCryf management to present at investor conferences on 16-18 November 2026.
Select text to share a quote on X · sign in to keep highlights & notes in your TCF notes
TheraCryf plc (AIM: TCF), the biotechnology company developing new medicines for addiction and other neuropsychiatric disorders, is pleased to announce its participation in the following investor conferences.
Management will be available to meet existing shareholders and prospective investors and answer questions about TheraCryf and its lead Ox-1 addiction programme.
LSX Investival Showcase – 16 November 2026
Dr Huw Jones, Chief Executive Officer, will present at the LSX Investival Showcase at Old Billingsgate, London, today, 16 November 2026, at 11.45 am.
TheraCryf will attend Mello London at the Clayton Hotel & Conference Centre, Chiswick, London, on Tuesday, 17 November 2026 and Wednesday, 18 November 2026.
The Company will present from 10.40-11.10 am on Tuesday, 17 November 2026 and from 2.25-2.55 pm on Wednesday, 18 November 2026.
These events follow the Company’s attendance at BIO-Europe in Cologne from 9–11 November 2026, where management met potential partners and industry colleagues to discuss TheraCryf’s development programmes.
The presentations will draw on information already in the public domain. No new material information will be disclosed.
Cleaned text: letterheads, contacts and legal notices removed. Official copy: FCA National Storage Mechanism ↗ · Company filings. Not investment advice.